Suppr超能文献

p38 通路的抑制导致大鼠动物模型出现类似 OA 的变化。

Inhibition of p38 pathway leads to OA-like changes in a rat animal model.

机构信息

Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove Campus, Brisbane, Queensland 4059, Australia.

出版信息

Rheumatology (Oxford). 2012 May;51(5):813-23. doi: 10.1093/rheumatology/ker360. Epub 2012 Jan 12.

Abstract

OBJECTIVES

The p38 mitogen-activated protein kinase (MAPK) signal transduction pathway is involved in a variety of inflammatory responses, including cytokine generation, cell differentiation proliferation and apoptosis. Here, we examined the effects of systemic p38 MAPK inhibition on cartilage cells and OA disease progression by both in vitro and in vivo approaches.

METHODS

p38 kinase activity was evaluated in normal and OA cartilage cells by measuring the amount of phosphorylated protein. To examine the function of p38 signalling pathway in vitro, normal chondrocytes were isolated and differentiated in the presence or absence of p38 inhibitor SB203580 and analysed for chondrogenic phenotype. Effect of systemic p38 MAPK inhibition in normal and OA (induced by menisectomy) rats were analysed by treating animals with vehicle alone [dimethylsulphoxide (DMSO)] or p38 inhibitor (SB203580). Damage to the femur and tibial plateau was evaluated by modified Mankin score, histology and immunohistochemistry.

RESULTS

Our in vitro studies have revealed that a down-regulation of chondrogenic and an increase of hypertrophic gene expression occurs in the normal chondrocytes when p38 is neutralized by a pharmacological inhibitor. We further observed that the basal levels of p38 phosphorylation were decreased in OA chondrocytes compared with normal chondrocytes. These findings together indicate the importance of this pathway in the regulation of cartilage physiology and its relevance to OA pathogenesis. At the in vivo level, systematic administration of a specific p38 MAPK inhibitor, SB203580, continuously for more than a month led to a significant loss of proteoglycan, aggrecan and cartilage thickness. On the other hand, SB203580-treated normal rats showed a significant increase in Terminal dUTP nick end-labelling (TUNEL)-positive cells, cartilage hypertrophy markers such as Type 10 collagen, Runt-related transcription factor and MMP-13 and substantially induced OA-like phenotypic changes in the normal rats. In addition, menisectomy-induced OA rat models that were treated with p38 inhibitor showed aggravation of cartilage damage.

CONCLUSIONS

In summary, this study has provided evidence that the component of the p38 MAPK pathway is important to maintain cartilage health, and its inhibition can lead to severe cartilage degenerative changes. The observations in this study highlight the possibility of using activators of the p38 pathway as an alternative approach in the treatment of OA.

摘要

目的

p38 丝裂原活化蛋白激酶(MAPK)信号转导通路参与多种炎症反应,包括细胞因子生成、细胞分化增殖和凋亡。在这里,我们通过体外和体内方法研究了全身性 p38MAPK 抑制对软骨细胞和 OA 疾病进展的影响。

方法

通过测量磷酸化蛋白的量来评估正常和 OA 软骨细胞中的 p38 激酶活性。为了研究 p38 信号通路在体外的功能,分离并分化正常软骨细胞,在存在或不存在 p38 抑制剂 SB203580 的情况下进行分析,以评估其软骨生成表型。通过用载体(二甲亚砜(DMSO))或 p38 抑制剂(SB203580)单独处理动物来分析全身性 p38MAPK 抑制对正常和 OA(通过半月板切除术诱导)大鼠的影响。通过改良的 Mankin 评分、组织学和免疫组织化学评估股骨和胫骨平台的损伤。

结果

我们的体外研究表明,当用药理学抑制剂中和 p38 时,正常软骨细胞中的软骨生成基因表达下调,而肥大基因表达增加。我们还观察到,与正常软骨细胞相比,OA 软骨细胞中的 p38 磷酸化基础水平降低。这些发现共同表明该途径在调节软骨生理学及其与 OA 发病机制的相关性方面具有重要意义。在体内水平,连续一个多月系统给予特定的 p38MAPK 抑制剂 SB203580 会导致蛋白聚糖、聚集蛋白聚糖和软骨厚度明显丢失。另一方面,SB203580 处理的正常大鼠的末端 dUTP 缺口末端标记(TUNEL)阳性细胞、I 型胶原、Runt 相关转录因子和 MMP-13 等软骨肥大标志物显著增加,并在正常大鼠中引起类似 OA 的表型变化。此外,用 p38 抑制剂治疗的半月板切除术诱导的 OA 大鼠模型显示出软骨损伤的加重。

结论

总之,本研究提供了证据表明 p38MAPK 途径的组成部分对于维持软骨健康很重要,其抑制可导致严重的软骨退行性变化。本研究中的观察结果强调了使用 p38 途径的激活剂作为 OA 治疗的替代方法的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验